Overview

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

Status:
Active, not recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance.
Phase:
Phase 3
Details
Lead Sponsor:
Bristol-Myers Squibb
ViiV Healthcare
Treatments:
Fostemsavir